Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Theriva Biologics ( (TOVX) ) has issued an update.
Theriva Biologics has announced that the European Commission granted orphan medicinal product designation to its leading candidate VCN-01 for treating retinoblastoma, highlighting the urgent need for new therapies. This designation, following similar recognition by the FDA, underscores VCN-01’s potential to transform treatment options, offering significant benefits to patients by enhancing chemotherapy effectiveness and improving immune response against tumors.
For a thorough assessment of TOVX stock, go to TipRanks’ Stock Analysis page.
